2024-10-22 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis:

**1. Performance Comparison:**

Abbott Laboratories (ABT), a healthcare company that develops, manufactures, and sells a wide range of healthcare products, has a cumulative return of 113.76% compared to the S&P 500 (VOO) with a cumulative return of 137.88%. This indicates ABT has underperformed the S&P 500 by 24.12%, placing it in the 17.29th percentile of its historical performance range relative to the index.

**2. Recent Price Trends:**

* Closing Price: $119.39
* 5-Day Moving Average: $117.68
* 20-Day Moving Average: $114.85
* 60-Day Moving Average: $112.91

The recent price trends suggest a short-term upward trend as the closing price is above all three moving averages.

**3. Technical Indicators:**

* RSI: 72.95
* PPO: 0.38
* 20-Day Relative Divergence: 3.39 (Positive, indicating a potential short-term upward trend)
* Expected Return: 0.0% (Expected long-term return relative to the S&P 500 over 2 years or more)

The RSI suggests the stock is in overbought territory, while the PPO indicates a positive momentum. The positive divergence indicates potential short-term upside. However, the expected return of 0.0% suggests limited long-term growth potential compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date      | EPS  | Revenue |
| ---------- | ---- | -------- |
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.70 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

The most recent earnings report (2024-07-31) showed EPS of $0.74, exceeding analysts' estimates by $0.04. Revenue of $10.38 billion also surpassed expectations. The company has shown consistent revenue growth with a slight dip in EPS in the recent quarter. 

**5. News and Recent Issues:**

* **Recent Market Outlook:**  While Abbott Laboratories has faced challenges from COVID-19 and supply chain disruptions, its diverse product portfolio and focus on innovation have allowed it to maintain strong performance. Continued growth is expected across its segments, with particular emphasis on the diagnostics and nutrition businesses.
* **Analyst Opinions:**  Analysts generally hold a positive view of ABT, with many rating it as a "buy" or "hold." Key strengths include its strong brand reputation, global reach, and commitment to research and development. Concerns include potential pricing pressure and regulatory scrutiny.
* **Performance Highlights:** ABT has consistently delivered solid financial results, exceeding expectations in recent quarters. The company's robust cash flow generation and dividend payments make it attractive to value investors.
* **Finbold:** Finbold reported in August 2024 that Abbott Laboratories' strong performance in the second quarter of 2024 was driven by solid growth in its medical devices, diagnostics, and nutrition segments. The report also highlighted ABT's commitment to expanding its global footprint and investing in new technologies.

**6. Overall Analysis:**

Abbott Laboratories is a stable and well-established healthcare company with a diverse product portfolio. While it has underperformed the S&P 500 in recent years, its strong fundamentals, consistent earnings growth, and positive market outlook make it a potential investment for those seeking long-term growth and dividend income. The stock is currently in overbought territory, but the short-term trends suggest potential upside. However, the limited expected return compared to the S&P 500 should be considered for long-term investments.

**7. Report Summary:**

Abbott Laboratories is a healthcare company with a diverse portfolio of products. While the stock has underperformed the S&P 500 in recent years, it has a strong track record of consistent earnings growth. The company's recent earnings report exceeded expectations, suggesting continued growth potential. The stock is currently in overbought territory but shows positive short-term trends. However, the limited expected return relative to the S&P 500 should be considered for long-term investments. Overall, ABT is a potential investment for those seeking stable growth and dividend income. 
